Doyle Wealth Management Grows Stock Position in Zoetis Inc. (NYSE:ZTS)

Doyle Wealth Management grew its stake in Zoetis Inc. (NYSE:ZTSGet Rating) by 0.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 56,948 shares of the company’s stock after acquiring an additional 493 shares during the period. Doyle Wealth Management’s holdings in Zoetis were worth $13,897,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Bluestein R H & Co. grew its stake in Zoetis by 2.3% during the 3rd quarter. Bluestein R H & Co. now owns 236,144 shares of the company’s stock worth $45,845,000 after purchasing an additional 5,400 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec lifted its stake in shares of Zoetis by 58.2% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 254,377 shares of the company’s stock worth $49,385,000 after acquiring an additional 93,548 shares during the period. Garrett Investment Advisors LLC acquired a new stake in shares of Zoetis in the 4th quarter valued at approximately $433,000. BOKF NA acquired a new position in Zoetis during the third quarter worth $10,158,000. Finally, Assetmark Inc. grew its position in shares of Zoetis by 3.1% in the third quarter. Assetmark Inc. now owns 85,431 shares of the company’s stock valued at $16,586,000 after purchasing an additional 2,595 shares during the last quarter. 90.73% of the stock is owned by institutional investors and hedge funds.

NYSE ZTS traded up $0.93 during trading hours on Tuesday, reaching $166.43. The company’s stock had a trading volume of 1,871,864 shares, compared to its average volume of 2,499,772. The company has a current ratio of 2.25, a quick ratio of 1.58 and a debt-to-equity ratio of 1.12. The business has a 50-day simple moving average of $184.08 and a 200 day simple moving average of $203.06. Zoetis Inc. has a 52 week low of $158.27 and a 52 week high of $249.27. The stock has a market cap of $78.33 billion, a PE ratio of 38.16, a PEG ratio of 2.77 and a beta of 0.77.

Zoetis (NYSE:ZTSGet Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.09. The business had revenue of $2 billion during the quarter, compared to analyst estimates of $1.98 billion. Zoetis had a return on equity of 49.62% and a net margin of 26.27%. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.26 EPS. As a group, equities analysts predict that Zoetis Inc. will post 5.06 EPS for the current year.

A number of research analysts have recently commented on the stock. Citigroup dropped their price objective on shares of Zoetis from $232.00 to $208.00 and set a “neutral” rating for the company in a research note on Wednesday, March 9th. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 26th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $235.29.

In other Zoetis news, CEO Kristin C. Peck sold 10,000 shares of the business’s stock in a transaction on Friday, February 25th. The stock was sold at an average price of $192.29, for a total transaction of $1,922,900.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Roxanne Lagano sold 2,167 shares of the company’s stock in a transaction that occurred on Tuesday, April 26th. The stock was sold at an average price of $178.96, for a total transaction of $387,806.32. Following the completion of the sale, the executive vice president now directly owns 23,687 shares of the company’s stock, valued at $4,239,025.52. The disclosure for this sale can be found here. Insiders have sold a total of 50,557 shares of company stock valued at $9,589,496 over the last three months. 0.12% of the stock is currently owned by company insiders.

Zoetis Company Profile (Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.